A single-compartment model cannot describe passive expiration in intubated, paralysed humans
…, JF Dhainaut, D Paccaly… - European …, 1991 - Eur Respiratory Soc
The time-course of thoracic volume changes (respiratory inductive plethysmograph) during
relaxed expiration was studied in 11 intubated, paralysed, mechanically ventilated subjects. …
relaxed expiration was studied in 11 intubated, paralysed, mechanically ventilated subjects. …
Modelling of passive expiration in patients with adult respiratory distress syndrome
…, A Chelucci, A Allegra, D Paccaly… - European …, 1993 - Eur Respiratory Soc
The time-course of volume change during passive expiration preceded by an end-inspiratory
hold was studied with a biexponential model in six adult respiratory distress syndrome (…
hold was studied with a biexponential model in six adult respiratory distress syndrome (…
Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler
…, S Newman, J Zhang, D Paccaly… - American journal of …, 2004 - journals.lww.com
A pharmacoscintigraphic study was conducted to compare the dose deposition of HMR 1031
from the existing nebulizer formulation and the new Ultrahaler device to help determine the …
from the existing nebulizer formulation and the new Ultrahaler device to help determine the …
Pharmacokinetic interactions between theophylline and rioprostil
…, E Rey, P Çathis, MO Richard, D Paccaly… - Scandinavian Journal …, 1989 - Taylor & Francis
The study is of double-blind crossover design. The effects of rioprostil, an analogue of
prostaglandin E, at a dose of 300 μg bd, and placebo on the kinetic of slow-release theophylline …
prostaglandin E, at a dose of 300 μg bd, and placebo on the kinetic of slow-release theophylline …
… ‐74: A model‐based approach for evaluating potential contamination of blood samples from a common indwelling catheter and its effects on estimated Actinomycin‐D …
DA Paccaly, JM Skolnik, PC Adamson… - Clinical …, 2006 - Wiley Online Library
INTRODUCTION A structural model derived from Actinomycin‐D (Act‐D) exposure following
dosing through a central venous line (CVL) and sampling from a peripheral vein was …
dosing through a central venous line (CVL) and sampling from a peripheral vein was …
Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients
…, LJ Geiter, CD Wells, AJ Paccaly… - … of tuberculosis and …, 2011 - ingentaconnect.com
… tuberculosis sur des plaques d’agar à partir de prélèvements des crachats nocturnes pour
calculer l’activité bactéricide précoce (EBA) définie sous forme d’une chute du log10 cfu/ml de …
calculer l’activité bactéricide précoce (EBA) définie sous forme d’une chute du log10 cfu/ml de …
[HTML][HTML] Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
…, R Passalacqua, S Li, K McGuire, M Kaul, A Paccaly… - Nature Medicine, 2022 - nature.com
First-line cemiplimab (anti-programmed cell death-1 (PD-1)) monotherapy has previously
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
shown significant improvement in overall survival (OS) and progression-free survival (PFS) …
Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters
C Xu, A Rafique, T Potocky, A Paccaly… - The Journal of …, 2021 - Wiley Online Library
We evaluated interleukin‐6 (IL‐6) receptor‐α subunit (IL‐6Rα) signaling inhibition with
sarilumab and tocilizumab, the association between IL‐6Rα receptor occupancy (RO) and C‐…
sarilumab and tocilizumab, the association between IL‐6Rα receptor occupancy (RO) and C‐…
[HTML][HTML] Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies
F Yang, AJ Paccaly, RK Rippley, JD Davis… - … of Pharmacokinetics and …, 2021 - Springer
Cemiplimab, a human monoclonal antibody targeting programmed cell death-1 (PD-1)
receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety …
receptor, demonstrated antitumor activity in patients with advanced malignancies and a safety …
Effect of an NK1/NK2 Receptor Antagonist on Airway Responses and Inflammation to Allergen in Asthma
…, J Cohen, PJ Sterk, B Miller, A Paccaly… - American journal of …, 2007 - atsjournals.org
Rationale: The tachykinins substance P and neurokinin A (NKA) are implicated in the
pathophysiology of asthma. Objective: We tested the safety, tolerability, and pharmacologic and …
pathophysiology of asthma. Objective: We tested the safety, tolerability, and pharmacologic and …